{"id":"NCT01976364","sponsor":"Pfizer","briefTitle":"Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis","officialTitle":"A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-17","primaryCompletion":"2019-05-20","completion":"2019-05-20","firstPosted":"2013-11-05","resultsPosted":"2020-05-21","lastUpdate":"2020-05-21"},"enrollment":686,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Psoriatic"],"interventions":[{"type":"DRUG","name":"Tofacitinib","otherNames":[]},{"type":"DRUG","name":"Tofacitinib","otherNames":[]},{"type":"DRUG","name":"Methotrexate","otherNames":["Sub-study"]},{"type":"DRUG","name":"Placebo Methotrexate","otherNames":["Sub-study"]}],"arms":[{"label":"Tofacitinib","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability and efficacy of tofacitinib in subjects with active PsA who have previously participated in randomized studies of tofacitinib for this indication.\n\nThis study will include a sub-study to evaluate the efficacy, safety and tolerability of tofacitinib 5 mg BID administered as monotherapy after methotrexate withdrawal compared to tofacitinib 5 mg BID continued in combination with methotrexate. The sub-study will be available to subjects who have completed at least 24 months of participation in the open-label extension study and meet eligibility criteria for the sub-study.","primaryOutcome":{"measure":"Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)","effectByArm":[{"arm":"All Participants","deltaMin":83.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":153,"countries":["United States","Australia","Belgium","Brazil","Bulgaria","Canada","Czechia","Germany","Hungary","Mexico","Poland","Russia","Slovakia","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["40241921","39702318","38279411","38273637","36958766","36931693","36526796","34870800","32816215","32506317","32006348","31112005"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921092&StudyName=Open-Label%20Extension%20Study%20Of%20Tofacitinib%20In%20Psoriatic%20Arthritis"]},"adverseEventsSummary":{"seriousAny":{"events":115,"n":686},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Urinary tract infection","Bronchitis","Hypertension"]}}